Mytolente (Lanreotide Acetate)

Lanreotide acetate binds selectively to somatostatin receptors subtype 2 (SSTR2) and subtype 5 (SSTR5) on endocrine cells. This binding blocks adenylate cyclase, lowering cyclic AMP and suppressing the release of several hormones—including growth hormone, insulin, glucagon, and gastrointestinal peptides—thereby reducing the hormonal excess that drives disease symptoms.

The dosing regimen for Mytolente is individualized and determined by the prescribing physician based on the patient’s condition, response, and tolerability. Clinicians may adjust the injection frequency and amount according to clinical guidelines and patient monitoring, so specific dose information should be obtained from the treating healthcare professional.

Safety data for lanreotide acetate in pregnancy and lactation are limited, and the drug is generally classified as contraindicated or to be used only if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives and risks with their physician.

To request Mytolente, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and any required import documentation.

The primary alternative to lanreotide acetate is octreotide, another somatostatin analog. Both agents suppress similar hormones, but lanreotide typically offers a longer dosing interval (often every 4 weeks) compared with octreotide’s more frequent dosing schedule. Choice between them depends on patient preference, tolerability, and physician assessment of efficacy.

Mytolente should be stored at 2‑8 °C (refrigerated) in its original packaging, protected from light. Do not freeze or shake the product. If temporary storage at room temperature is unavoidable, limit exposure to less than 24 hours and return the product to refrigeration promptly.

Mytolente is given as a subcutaneous injection, usually performed by a healthcare professional. The injection site is typically the abdomen or thigh, and the volume administered depends on the prescribed dose. Patients should be instructed on proper injection technique and rotating sites to minimize local reactions.

Serious adverse events associated with lanreotide acetate include gallbladder disease (such as gallstones or cholecystitis), hyperglycemia that may worsen diabetes control, and pancreatitis presenting with severe abdominal pain. Rarely, anaphylactic reactions can occur. Prompt medical evaluation is essential if any of these symptoms develop.

Mytolente is contraindicated in individuals with known hypersensitivity to lanreotide acetate or any of the formulation excipients. Caution is also advised for patients with severe uncontrolled diabetes, active gallbladder disease, or those receiving other somatostatin analogs, as additive effects may increase the risk of hormonal suppression.